cell-free stem cell-derived extract / General Therap - LARVOL DELTA

Cell-free Stem Cell-derived Extract Formulation for Knee Osteoarthritis (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: General Therapeutics | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology • CRP

Cell-free stem cell-derived extract formulation for treatment of knee osteoarthritis: study protocol for a preliminary non-randomized, open-label, multi-center feasibility and safety study. (PubMed, J Orthop Surg Res) - P1 | "This prospective study will provide valuable information into the safety and efficacy of intraarticular administration of cell-free stem cell-derived extract (CCM) in patients suffering with grade II/III knee OA. The outcomes from this initial study of novel CCM will lay the foundation for a larger randomized, placebo-controlled, multi-center clinical trial of intraarticular CCM for symptomatic knee OA."

Clinical • Journal • Immunology • Musculoskeletal Diseases • Osteoarthritis • Pain • Rheumatology • MRI

Cell-free Stem Cell-derived Extract Formulation for Knee Osteoarthritis (clinicaltrials.gov) - P1; N=12; Not yet recruiting; Sponsor: General Therapeutics

Clinical • New P1 trial • Immunology • Osteoarthritis • Pain • Rheumatology • CRP